Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Autoimmune Disorders01:29

Autoimmune Disorders

2.4K
Autoimmune diseases are a group of disorders in which the body's immune system mistakenly attacks its own cells, tissues, and organs. This results from an overactive immune response against substances and tissues normally present in the body. Let's delve into the concept and mechanism of autoimmune diseases from an immune system point of view, explore different causes and examples of such diseases, and discuss potential solutions.
Concept and Mechanism of Autoimmune Diseases
The immune...
2.4K
Graves' Disease I: Introduction01:28

Graves' Disease I: Introduction

23
Graves' disease is an autoimmune disorder that causes hyperthyroidism, or overactivity of the thyroid gland. It results from autoantibodies called thyroid-stimulating immunoglobulins (TSIs), which bind to thyroid-stimulating hormone (TSH) receptors, leading to overstimulation of hormone production and a hypermetabolic state.EtiologyAlthough considered idiopathic, Graves’ disease has well-established contributing factors. There is a strong genetic component, with increased prevalence...
23
T Cell Types and Functions01:24

T Cell Types and Functions

3.2K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
3.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Munc13-4-STX7 inhibitors impair endosomal TLR activation and systemic inflammation.

Nature chemical biology·2026
Same author

Stalling the Enemy: Targeting Nsp13 for Next-Generation SARS-CoV-2 Antivirals.

International journal of molecular sciences·2026
Same author

Human RIG-I Antiviral Deficiency Caused by a Dominant-Negative Variant Locked in a Signaling-Inactive State.

medRxiv : the preprint server for health sciences·2026
Same author

PAR-Driven Condensation Maintains Stalled Replication Fork Stability.

bioRxiv : the preprint server for biology·2026
Same author

Structural determinants of non-covalent PPARγ inverse agonism and their therapeutic implications.

Nature communications·2025
Same author

A ternary switch model governing ERα ligand binding domain conformation.

Nature communications·2025

Related Experiment Video

Updated: May 1, 2026

Experimental Autoimmune Uveitis: An Intraocular Inflammatory Mouse Model
07:40

Experimental Autoimmune Uveitis: An Intraocular Inflammatory Mouse Model

Published on: January 12, 2022

5.3K

RORs in autoimmune disease.

Mi Ra Chang1, Hugh Rosen, Patrick R Griffin

  • 1Department of Molecular Therapeutics, The Scripps Research Institute, Scripps Florida, Jupiter, FL, 33458, USA.

Current Topics in Microbiology and Immunology
|April 15, 2014
PubMed
Summary
This summary is machine-generated.

Pharmacological repression of retinoic acid receptor-related orphan receptor gamma t (RORγt) may treat autoimmune diseases. This research summarizes RORγt target validation and new drug development for autoimmune disorder therapies.

More Related Videos

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
09:38

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

16.0K
An Adoptive Transfer Model of Rheumatoid Arthritis in Mice
07:37

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice

Published on: June 6, 2025

1.5K

Related Experiment Videos

Last Updated: May 1, 2026

Experimental Autoimmune Uveitis: An Intraocular Inflammatory Mouse Model
07:40

Experimental Autoimmune Uveitis: An Intraocular Inflammatory Mouse Model

Published on: January 12, 2022

5.3K
Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
09:38

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

16.0K
An Adoptive Transfer Model of Rheumatoid Arthritis in Mice
07:37

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice

Published on: June 6, 2025

1.5K

Area of Science:

  • Immunology
  • Molecular Biology
  • Pharmacology

Background:

  • Nuclear receptors, including the retinoic acid receptor-related orphan receptor (ROR) subfamily, regulate gene transcription.
  • ROR subfamily members are crucial for circadian rhythm and immune system regulation.
  • The T cell-specific isoform, RORγt, is essential for T helper 17 (TH17) cell development.

Purpose of the Study:

  • To summarize the current status of RORγt target validation.
  • To review the development of novel chemical entities targeting RORγt.
  • To explore the therapeutic potential of RORγt inhibition in autoimmune diseases.

Main Methods:

  • Review of scientific literature on RORγt function and pharmacology.
  • Analysis of target validation strategies for RORγt.
  • Summary of drug discovery efforts for RORγt inhibitors.

Main Results:

  • RORγt plays a critical role in TH17 cell differentiation.
  • RORγt is implicated in the pathogenesis of autoimmune diseases like multiple sclerosis and rheumatoid arthritis.
  • Pharmacological repression of RORγt is a promising therapeutic strategy.

Conclusions:

  • RORγt is a validated therapeutic target for autoimmune disorders.
  • Development of small molecule inhibitors targeting RORγt is ongoing.
  • Targeting RORγt offers a potential new avenue for treating autoimmune conditions.